GlassScriptPhysician profile
Kongmong Moua
NPI 1811009244
$4,229.50
in general payments reported to CMS, 2019-2025
25 companies · $617 in 2025
The $617 reported for 2025 was more than what 75% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $937 · 2022: $1,544 · 2023: $657 · 2024: $476 · 2025: $617.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,749.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,749.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $807.01 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Amgen INC. | $563.36 | 2021-2025 | Repatha, Otezla, Otezla |
| Astrazeneca Pharmaceuticals LP | $333.63 | 2021-2025 | Airsupra, Breztri, Farxiga |
| Pfizer INC. | $307.84 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $294.49 | 2021-2022 | |
| Gilead Sciences, INC. | $240.39 | 2021-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $223.87 | 2023-2025 | |
| Dexcom, INC. | $204.25 | 2022-2025 | Dexcom G6 Transmitter |
| Nestle Healthcare Nutrition INC. | $156.20 | 2021-2023 | |
| Abbott Laboratories | $148.22 | 2021-2025 | Freestyle Libre 3 |
| Novo Nordisk INC | $147.17 | 2021-2025 | Rybelsus, Ozempic |
| Abbvie INC. | $120.85 | 2022-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $112.39 | 2022 | |
| Glaxosmithkline, LLC. | $91.94 | 2021-2024 | Trelegy Ellipta |
| Biohaven Pharmaceuticals, INC. | $81.71 | 2021 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $68.44 | 2021-2025 | |
| Exact Sciences Corporation | $59.49 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Sanofi Pasteur INC. | $54.03 | 2021-2023 | |
| Sumitomo Pharma America, INC. | $50.57 | 2025 | Gemtesa |
| Alkermes, INC. | $43.08 | 2021-2024 | Vivitrol |
| Aimmune Therapeutics, INC. | $40.86 | 2024 | |
| Novartis Pharmaceuticals Corporation | $26.66 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $24.38 | 2025 | Dupixent |
| Vbi Vaccine (Delaware) INC. | $14.66 | 2022 | |
| Dynavax Technologies Corporation | $14.01 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kongmong Moua listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.